Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

Hepatic Drug Excretion: Enterohepatic Cycling

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Effects of the start date of refrigeration on functions of delayed cold-stored platelets.

Vox sanguinis·2026

Same author

Human platelet lysate produced from leukoreduction filter contents enables sufficient MSC growth.

Stem cell research & therapy·2025

Same author

Gastric carcinoma of the fundic gland type developed 32 years after <i>Helicobacter pylori</i> eradication for duodenal ulcer: a case report.

Annals of medicine and surgery (2012)·2024

Same author

Matrix metalloproteinase‑1 and microRNA‑486‑5p in urinary exosomes can be used to detect early lung cancer: A preliminary report.

Oncology letters·2024

Same author

Anti-acid treatment for ulcerated early gastric cancer may be a treatment option avoiding unnecessary gastrectomy: a cohort study.

Annals of medicine and surgery (2012)·2023

Same author

Primary small-cell carcinoma in the lung was found after the cold snare polypectomy of the small metastatic lesion in the cecum: A case report.

DEN open·2023

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

[Cyclophosphamide and CYP2B6].

Yoshihiro Torimoto¹, Yutaka Kohgo

¹Oncology Center, Asahikawa Medical College Hospital, Hokkaido, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy

|July 18, 2008

Summary

Genetic variations in CYP2B6 influence cyclophosphamide (CPA) metabolism. Specific CYP2B6 polymorphisms, like CYP2B6*6, impact CPA clearance and half-life, affecting patient response and safety. Further research is needed for clinical application.

Area of Science:

Pharmacogenomics
Drug Metabolism
Cytochrome P450 Superfamily

Context:

Hepatic cytochrome P450 (CYP) enzymes are crucial for drug metabolism, exhibiting significant individual variability.
CYP gene polymorphisms are a primary driver of these metabolic differences, impacting drug efficacy and adverse reactions.
Cyclophosphamide (CPA) biotransformation to 4-hydroxy-CPA by hepatic CYPs is essential for its therapeutic effect.

Purpose:

To investigate the role of CYP2B6 gene polymorphisms in cyclophosphamide (CPA) metabolism.
To explore how specific CYP2B6 alleles, such as CYP2B6*6, affect CPA pharmacokinetics and patient outcomes.
To assess the current understanding of CYP2B6 polymorphism in predicting CPA therapy efficacy and safety.

Summary:

CYP2B6 is identified as a key enzyme in CPA metabolism, with its high polymorphism contributing to variable drug response.

More Related Videos

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Experiment Videos

Last Updated: Jul 3, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

The CYP2B6*6 allele, common in Japanese populations, alters CYP2B6 activity, leading to increased CPA clearance and shorter half-life in homozygous patients.

Other CYP2B6 polymorphisms also impact CPA metabolism, but current knowledge is insufficient for precise clinical prediction.

Impact:

Highlights the clinical significance of CYP2B6 genetic variations in CPA treatment for various cancers and autoimmune diseases.
Underscores the need for further research to establish CYP2B6 polymorphism as a reliable biomarker for personalized CPA therapy.
Emphasizes the potential for pharmacogenomic approaches to optimize CPA dosing and minimize adverse events.